Calliditas’ Nefecon Meets its Primary Endpoint in P-III Trial (NefIgArd) for the Treatment of IgA Nephropathy
- The P-III trial (NefIgArd) evaluating Tarpeyo (16mg, qd) vs PBO in a ratio (1:1) in 364 patients as an addition to optimized RAS inhibitor therapy. Part A of the study incl. a 9mos. blinded treatment period & 3mos. follow-up period while Part B incl. a 12mos. observational period
- The trial met its 1EPs & showed a benefit in eGFR over 2yr. period of 9mos. of treatment & 15mos. of follow-up, 2yr. total slope analyses reflected a sustained treatment benefit, UPCR reductions reflected a treatment effect during the 15mos. the follow-up period. The therapy was well-tolerated & safety profile was consistent with Part A of the trial
- Nefecon was marketed under the brand name Tarpeyo in the US & by STADA Arzneimittel AG in the EEA, Switzerland & the UK under Kinpeygo
Ref: Prnewswire | Image: Calliditas
Related Post:- Calliditas’ Kinpeygo Receive EC's Marketing Authorization for the Treatment of Primary Immunoglobulin A Nephropathy
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].